BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 225 filers reported holding BRIDGEBIO PHARMA INC in Q3 2023. The put-call ratio across all filers is 0.81 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $35,368,578 | +25.9% | 1,341,243 | -17.9% | 0.04% | +27.6% |
| Q2 2023 | $28,087,359 | -24.1% | 1,632,986 | -26.8% | 0.03% | -27.5% |
| Q1 2023 | $37,006,908 | +79.8% | 2,232,021 | -17.4% | 0.04% | +73.9% |
| Q4 2022 | $20,580,279 | -12.2% | 2,700,824 | +14.5% | 0.02% | -17.9% |
| Q3 2022 | $23,439,000 | +5.4% | 2,358,069 | -3.7% | 0.03% | +7.7% |
| Q2 2022 | $22,232,000 | -12.2% | 2,448,459 | -1.9% | 0.03% | +8.3% |
| Q1 2022 | $25,335,000 | +18.1% | 2,496,028 | +94.1% | 0.02% | +33.3% |
| Q4 2021 | $21,452,000 | +174.7% | 1,286,089 | +672.0% | 0.02% | +157.1% |
| Q3 2021 | $7,808,000 | -24.1% | 166,592 | -1.3% | 0.01% | -22.2% |
| Q2 2021 | $10,286,000 | +548.1% | 168,734 | +555.0% | 0.01% | +350.0% |
| Q1 2021 | $1,587,000 | -51.4% | 25,759 | -77.1% | 0.00% | -60.0% |
| Q1 2020 | $3,265,000 | – | 112,589 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 6,068,125 | $55,099,000 | 39.31% |
| M28 Capital Management LP | 466,200 | $4,233,000 | 4.74% |
| Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $282,034,000 | 3.75% |
| Octagon Capital Advisors LP | 933,743 | $8,478,000 | 2.26% |
| VIKING GLOBAL INVESTORS LP | 26,620,991 | $241,719,000 | 1.11% |
| HHLR ADVISORS, LTD. | 5,362,014 | $48,687,000 | 1.04% |
| Cormorant Asset Management, LP | 1,469,179 | $13,340,000 | 1.01% |
| Knott David M Jr | 213,206 | $1,936,000 | 0.81% |
| Fernwood Investment Management, LLC | 183,900 | $1,670,000 | 0.72% |
| HighVista Strategies LLC | 105,942 | $962,000 | 0.58% |